Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 324

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 324
---
 any then-outstanding preferred stock, the holders of common stock are entitled to receive
ratably dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding-up, holders of our common stock will be
entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any
outstanding shares of preferred stock.

Rights, Preferences, and Privileges

Holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may
designate and issue in the future.

Fully Paid and Nonassessable

All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and
nonassessable.

217

Preferred Stock

As of June 30, 2025, there were 78,072,306 shares of redeemable convertible preferred stock outstanding, held of record by 298
stockholders. Upon the closing of this offering, all of the outstanding shares of redeemable convertible preferred stock will automatically convert into 3,181,815 shares of our common stock (including 382,467 additional shares of common stock
issuable upon conversion of our Series C convertible preferred stock due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on
the cover page of this prospectus).

Based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the
estimated offering price range set forth on the cover page of this prospectus, the 73,820,346 shares of our Series C convertible preferred stock outstanding prior to the Stock Split would convert into 3,029,425 shares of our common stock including
382,467 shares of common stock issuable in respect of anti-dilution adjustments. A $1.00 decrease in the initial public offering price would increase the number of shares of